Parkinson Disease
Conditions
Interventions
Up to 30 subjects are estimated to participate in the study, divided into two arms
(intervention and placebo). The intervention patients will be prescribed the initial use of 1
(one) 50mg tablet of tr
Drug
Sponsors
Universidade Federal da Integração Latino-Americana do Brasil (UNILA).
Universidade Federal da Integração Latino-Americana do Brasil (UNILA).
Eligibility
Inclusion criteria
Inclusion criteria: Individuals with PD clinically diagnosed according to the London Brain Bank criteria. Individuals who voluntarily agree with the procedures and information of the Free and Informed Consent Form. Have cognitive function that allows the understanding of past information by the researcher during the tests (Mini Mental State Examination). Do not present conditions that hinder or impede the movement of the upper limbs, such as: surgeries in the last 12 months; musculotendinosus injuries; fractures; use of prostheses or prostheses; other associated neurological or neurodegenerative conditions; etc. Individuals classified in phase 3 of the Hoeh and Yahr scale.
Exclusion criteria
Exclusion criteria: Withdrawal from participation in the research. Incomplete completion of the instruments. Individuals with treatment abandonment. Patients with symptoms of parkinsonism induced by exogenous intoxication, infectious, vascular, metabolic, genetic causes, other degenerative diseases or by drugs - such as dopaminergic receptor blockers, anticholinesterases, anticonvulsants, antiarrhythmics, reserpine, tetrabenazine, alfamethyldopa, lithium and fluoxetine. Patients who do not want to stop using monoamine oxidase (MAO) inhibitor drugs. Patients who do not interrupt the use of monoamine oxity (MAO) inhibitor drugs in 15 days before the start of the survey. MAO inhibitors are considered, among others, the following medications: Phenelzine; Iproniazid; Isocarboxazide; Harmalina; Nialamide; Pargyline; Selegiline; Toloxatone; Tranilcipromina. Patients who need to use the linezolid antibiotic, digoxin or phenytoin during the experiment. Diabetic patients or patients with other chronic diseases. Individuals with cardiac disorders or in the recovery phase of an acute myocardial infarction . Patients with reports of psychological disorders such as schizophrenia or bipolar disorder. Patients with renal or hepatic impairment. Pregnant or lactating patients. Patients who have changed the treatment of PD in the past 03 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| As a null hypothesis, it will be assumed that the placebo and intervention groups will show equal results in measuring the motor effects of Parkinson's disease. Therefore, the intervention does not result in improvement of these symptoms. As an alternative hypothesis, it will be assumed that the placebo and intervention groups will present different results in measuring the motor effects of the disease Parkinson's disease, where the intervention group will present a lower result (score) compared to to the placebo group. Therefore, the intervention results in improvements in these symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| Possible improvements in the patient's general condition. | — |
Countries
Brazil
Contacts
Public ContactGilvan da Silva
Universidade Federal da Integração Latino-Americana do Brasil (UNILA).
Outcome results
None listed